Progress in gynecologic cancer detection and treatment

International Journal of Gynecology and Obstetrics

Volumn 70, Issue 1, 2000, Pages 135-147

  Benedet, J L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer; Gynecology; Progress; Quality of life

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; FEMALE; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; UTERINE CERVIX CANCER;

EID: 0034237316     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(00)00232-0     Document Type: Article

References (72)

1. Regaud C. What is the value and what should be the organization and equipment of institutes for the treatment of cancer by radium and X-rays. Surg Gynecol Obstet. 44:1927;116-140.
2. Greenough R.B. The radiological treatment of cancer. Surg Gynecol Obstet. 44:1927;108-115.
3. Babes A. La Presse Medicale. 29:1928;451-454.
4. Papanicolaou GN. New cancer diagnosis. In: Proceedings of the Third Race Betterment Conference, 1928. Battle Creek, MI; 1928. p. 528.
5. Papanicolaou G.N., Traut H.F. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 42(2):1941;193-206.
6. Heyman J. Atlas. Stockholm: Kungl. Boktryckeriet. 1938;P.A. Norstedt & Soner.
7. Statements of Results Obtained in 1930 and Previous Years. Stockholm: League of Nations Health Organisation, 1937.
8. Benedet J., Odicino F., Maisonneuve P., Severi G., Creasman W., Shepherd J. et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 3(1):1998;5-34.
9. Creasman W., Odicino F., Maisonneuve P., Benedet J., Shepherd J., Sideri M. et al. Carcinoma of the corpus uteri. J Epidemiol Biostat. 3(1):1998;35-61.
10. Pecorelli S., Odicino F., Maisonneuve P., Creasman W., Shepherd J., Sideri M. et al. Carcinoma of the fallopian tube. J Epidemiol Biostat. 3(1):1998;63-74.
11. Pecorelli S., Odicino F., Maisonneuve P., Creasman W., Shepherd J., Sideri M. et al. Carcinoma of the ovary. J Epidemiol Biostat. 3(1):1998;75-102.
12. Shepherd J., Sideri M., Benedet J., Maisonneuve P., Pecorelli S., Odicino F. et al. Carcinoma of the vagina. J Epidemiol Biostat. 3(1):1998;103-109.
13. Shepherd J., Sideri M., Benedet J., Maisonneuve P., Severi G., Pecorelli S. et al. Carcinoma of the vulva. J Epidemiol Biostat. 3(1):1998;111-127.
14. Creasman W., Odicino F., Maisonneuve P., Benedet J., Sideri M., Pecorelli S. et al. Gestational trophoblastic diseases. J Epidemiol Biostat. 3(1):1998;129-135.
15. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 54(4):1993;594-606.
16. Brinton L.A., Fraumeni J.F. Jr. Epidemiology of uterine cervical cancer. J Chronic Dis. 39(12):1986;1051-1065.
17. Brinton L.A., Hamman R.F., Huggins G.R., Lehman H.F., Levine R.S., Mallin K. et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst. 79(1):1987;23-30.
18. La Vecchia C., Franceschi S., Decarli A., Fasoli M., Gentile A., Tognoni G. Cigarette smoking and the risk of cervical neoplasia. Am J Epidemiol. 123(1):1986;22-29.
19. Rotkin I.D. A comparison review of key epidemiological studies in cervical cancer related to current searches for transmissible agents. Cancer Res. 33(6):1973;1353-1367.
20. Kessler I.I. Cervical cancer epidemiology in historical perspective. J Reprod Med. 12(5):1974;173-185.
21. Hulka B.S. Risk factors for cervical cancer. J Chronic Dis. 35(1):1982;3-11.
22. Rotkin I.D. Epidemiology of cancer of the cervix. 3. Sexual characteristics of a cervical cancer population. Am J Public Health Nations Health. 57(5):1967;815-829.
23. Munoz K.A., Harlan L.C., Trimble E.L. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol. 15(11):1997;3408-3415.
24. Ho G.Y.F., Bierman R., Beardsley L., Chee J.C., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 338:1998;423-428.
25. Palefsky J.M., Holly E.A. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev. 4:1995;415-428.
26. Ziel H.K., Finkle W.D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 293(23):1975;1167-1170.
27. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 85(2):1995;304-313.
28. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial [see comments]. J Am Med Assoc 1996;275(5):370-5.
29. Persson I., Schmidt M., Adami H.O., Bergstrom R., Pettersson B., Sparen P. Trends in endometrial cancer incidence and mortality in Sweden, 1960-84. Cancer Causes Control. 1(3):1990;201-208.
30. Persson I., Adami H.O., Bergkvist L., Lindgren A., Pettersson B., Hoover R. et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J. 298(6667):1989;147-151.
31. Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D. et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 40(1):1991;55-65.
32. Boronow R.C., Morrow C.P., Creasman W.T., Disaia P.J., Silverberg S.G., Miller A. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 63(6):1984;825-832.
33. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study, suppl 8. Cancer. 60:1987;2035-2041.
34. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316(11):650-5.
35. Fathalla M.F. Incessant ovulationa factor in ovarian neoplasia? Lancet. 2(7716):1971;163.
36. Rosenberg L., Shapiro S., Slone D., Kaufman D.W., Helmrich S.P., Miettinen O.S. et al. Epithelial ovarian cancer and combination oral contraceptives. Jama. 247(23):1982;3210-3212.
37. La Vecchia C., Franceschi S., Decarli A. Oral contraceptive use and the risk of epithelial ovarian cancer. Br J Cancer. 50(1):1984;31-34.
38. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989;18(3):538-45.
39. Heintz A.P., Van Oosterom A.T., Trimbos J.B., Schaberg A., Van der Velde E.A., Nooy M. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol. 30(3):1988;347-358.
40. Hoskins W.J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer, suppl 4. Cancer. 71:1993;1534-1540.
41. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334(1):1996;1-6.
42. van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer [see comments]. N Engl J Med. 332(10):1995;629-634.
43. Surwit E., Childers J., Atlas I., Nour M., Hatch K., Hallum A. et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 6:1996;356-361.
44. Gershenson D.M. Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors. Semin Surg Oncol. 10(4):1994;290-298.
45. Bagshawe K.D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 38(3):1976;1373-1385.
46. Berkowitz R.S., Goldstein D.P., Bernstein M.R. Methotrexate infusion and folinic acid in the primary therapy of nonmetastatic gestational trophoblastic tumors. Gynecol Oncol. 36(1):1990;56-59.
47. Newlands E.S., Bagshawe K.D., Begent R.H., Rustin G.J., Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol. 98(6):1991;550-557.
48. Way S. Ann R Coll Surg Engl. 3:1948;187.
49. Homesley H.D., Bundy B.N., Sedlis A., Yordan E., Berek J.S., Jahshan A. et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) [see comments]. Gynecol Oncol. 49(3):1993;279-283.
50. Paladini D., Cross P., Lopes A., Monaghan J.M. Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva [see comments]. Cancer. 74(9):1994;2491-2496.
51. Rutledge F.N., Mitchell M.F., Munsell M.F., Atkinson E.N., Bass S., McGuffee V. et al. Prognostic indicators for invasive carcinoma of the vulva. Gynecol Oncol. 42(3):1991;239-244.
52. Stehman F.B., Bundy B.N., Dvoretsky P.M., Creasman W.T. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 79(4):1992;490-497.
53. Grimshaw R.N., Murdoch J.B., Monaghan J.M. Radical vulvectomy and bilateral inguinal-femoral lymphadenopathy through separate incisions: experience with 100 cases. Int J Gynecol Cancer. 3:1993;18-23.
54. Iversen T., Abeler V., Aalders J. Individualized treatment of stage I carcinoma of the vulva. Obstet Gynecol. 57(1):1981;85-89.
55. Homesley H.D., Bundy B.N., Sedlis A., Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 68(6):1986;733-740.
56. Thomas G., Dembo A., DePetrillo A., Pringle J., Ackerman I., Bryson P. et al. Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol Oncol. 34(3):1989;263-267.
57. Hacker N.F., Berek J.S., Juillard G.J., Lagasse L.D. Preoperative radiation therapy for locally advanced vulvar cancer. Cancer. 54(10):1984;2056-2061.
58. National Cancer Institute of Canada. Canadian Cancer Statistics 1998. Toronto: Canadian Cancer Society; 1998.
59. International Agency for Research on Cancer: Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon: IARC; 1986.
60. Peto R., Lopez A.D., Boreham J., Thun M., Heath C. Jr. Mortality from tobacco in developed countries: indirect estimation from national vital statistics [see comments]. Lancet. 339(8804):1992;1268-1278.
61. Boyle P. Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer. 17(1):1997;1-60.
62. Ewertz M., Duffy S.W., Adami H.O., Kvale G., Lund E., Meirik O. et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer. 46(4):1990;597-603.
63. Kvale G., Heuch I., Eide G.E. A prospective study of reproductive factors and breast cancer. I. Parity. Am J Epidemiol. 126(5):1987;831-841.
64. Trichopoulos D., Hsieh C.C., MacMahon B., Lin T.M., Lowe C.R., Mirra A.P. et al. Age at any birth and breast cancer risk. Int J Cancer. 31(6):1983;701-704.
65. Howe H.L., Senie R.T., Bzduch H., Herzfeld P. Early abortion and breast cancer risk among women under age 40. Int J Epidemiol. 18(2):1989;300-304.
66. Lipworth L., Katsouyanni K., Ekbom A., Michels K.B., Trichopoulos D. Abortion and the risk of breast cancer: a case-control study in Greece [see comments]. Int J Cancer. 61(2):1995;181-184.
67. Daling J.R., Brinton L.A., Voigt L.F., Weiss N.S., Coates R.J., Malone K.E. et al. Risk of breast cancer among white women following induced abortion. Am J Epidemiol. 144(4):1996;373-380.
68. Breast cancer and hormone replacement therapy: Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52 705 Women with Breast Cancer and 108 ,411 Women Without Breast Cancer. Collaborative Group on Hormonal Factors in Breast Cancer [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet 1997;350(9084):1047-59.
69. Breast cancer and hormone replacement therapy: Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52 705 Women with Breast Cancer and 108 ,411 Women Without Breast Cancer. Collaborative Group on Hormonal Factors in Breast Cancer [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet 1997;350(9084):1047-59.
70. Prentice R.L., Thomas D.B. On the epidemiology of oral contraceptives and disease. Adv Cancer Res. 49:1987;285-401.
71. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer [see comments]. Lancet 1996;347(9017):1713-27.
72. Hulka B.S., Liu E.T., Lininger R.A. Steroid hormones and risk of breast cancer, suppl 3. Cancer. 74:1994;1111-1124.